MGD024

Treatment Description

MGD024 is a bispecific antibody that targets CD123 on cancer cells and CD3 on immune T cells. It is currently being studied for use in several different cancers.

Participating Centers

There are 7 centers running trials with this treatment. Enter a location below to find the closest center.